Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.73 |
| ▸ | HPGD | P15428 | 6/20 | 0.73 |
| ▸ | GAA | P10253 | 8/20 | 0.66 |
| ▸ | GLA | P06280 | 7/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | STS | P08842 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hymecromone Methyl Ether SCHEMBL314248 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| Hymecromone Methyl Ether SCHEMBL31103478 | 0.85 | KDM4E (1.00) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL15842390 | 0.82 | ALDH1A1 (0.71) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL20703812 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL14477795 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL66273 | 0.81 | ALDH1A1 (0.78) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL31281633 | 0.81 | KDM4E (1.00) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL14176760 | 0.81 | KDM4E (1.00) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL29557901 | 0.81 | ALDH1A1 (0.78) | ALDH1A1KDM4EHSD17B10HPGDGAA | |
| SCHEMBL335474 | 0.80 | KDM4E (1.00) | ALDH1A1KDM4EHSD17B10HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020218950-A1 | COMBINATION FOR TREATING FUNCTIONAL DISEASES OF THE GASTROINTESTINAL TRACT | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2020-10-29 | — | — | WO | claimed |
| WO-2020218950-A4 | COMBINATION FOR TREATING FUNCTIONAL DISEASES OF THE GASTROINTESTINAL TRACT | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2021-01-14 | — | — | WO | disclosed |
| WO-2020218950-A1 | COMBINATION FOR TREATING FUNCTIONAL DISEASES OF THE GASTROINTESTINAL TRACT | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2020-10-29 | — | — | WO | disclosed |
| WO-2020218950-A1 | COMBINATION FOR TREATING FUNCTIONAL DISEASES OF THE GASTROINTESTINAL TRACT | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ВАЛЕНТА-ИНТЕЛЛЕКТ" | 2020-10-29 | — | — | WO | disclosed |
| US-8729232-B2 | Aldehyde tags, uses thereof in site-specific protein modification | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-05-20 | — | — | US | disclosed |
| US-8349910-B2 | Aldehyde tags, uses thereof in site-specific protein modification | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-08 | — | — | US | disclosed |
| US-7846965-B2 | a non-steroidal sulphamate compound such as 6-Oxo-8,9,10,11-tetrahydro-7H-cyclohepta-[c][1]benzopyran-3-O-sulphamate, suitable for use as an inhibitor of estrone sulphatase, for the treatment of endocrine-dependent cancers and tumors, such as the breast and endometrium | STERIX LIMITED (GB) | 2010-12-07 | — | — | US | disclosed |
| US-20070173531-A1 | Compound | REED MICHAEL J | 2007-07-26 | — | — | US | disclosed |
| US-7202272-B2 | Compound | STERIX, LTD. (GB) | 2007-04-10 | — | — | US | disclosed |
| US-20070021624-A1 | Steroid sulphatase inhibitors | REED MICHAEL J | 2007-01-25 | — | — | US | disclosed |
| US-6642397-B1 | Purified polycyclic sulfamate derivative | STERIX LIMITED (GB) | 2003-11-04 | — | — | US | disclosed |
| US-6476011-B1 | Methods for introducing an estrogenic compound | STERIX LIMITED (GB) | 2002-11-05 | — | — | US | disclosed |
| US-20020128243-A1 | Steroid sulphatase inhibitors | REED MICHAEL JOHN (GB) | 2002-09-12 | — | — | US | disclosed |
| US-20010018435-A1 | Steroid sulphatase inhibitors | STERIX LIMITED | 2001-08-30 | — | — | US | disclosed |
| US-6239169-B1 | ANTICARCINOGENIC AGENTS; AUTOIMMUNE DISEASES | STERIX LIMITED (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6187766-B1 | Steroid sulphatase inhibitors | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) | 2001-02-13 | — | — | US | disclosed |
| US-6159960-A | Steroid sulphatase inhibitors | STERIX LIMITED (GB) | 2000-12-12 | — | — | US | disclosed |
| US-6011024-A | A RING SYSTEM COMPOUND TO WHICH IS ATTACHED A SULPHAMATE GROUP | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY & MEDICINE (GB) | 2000-01-04 | — | — | US | disclosed |
| EP-0880514-A1 | NON-STEROIDAL POLYCYCLIC RING SULPHAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS OESTRONE SULPHATASE INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030041-A1 | NON-STEROIDAL POLYCYCLIC RING SULPHAMATE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS OESTRONE SULPHATASE INHIBITORS | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021624-A1 | Steroid sulphatase inhibitors | STS, CYP21A2, SULT1E1 | ALDH1A1 365/4885KDM4E 1652/4885HSD17B10 39/4885 |
| US-20070173531-A1 | Compound | HSD17B11, NR5A1, CYP17A1 | ALDH1A1 611/4885KDM4E 1129/4885HSD17B10 24/4885 |
| US-20010018435-A1 | Steroid sulphatase inhibitors | STS, CYP21A2, SULT1E1 | ALDH1A1 326/4885KDM4E 1805/4885HSD17B10 39/4885 |
| US-20020128243-A1 | Steroid sulphatase inhibitors | STS, SULT1E1, CYP21A2 | ALDH1A1 398/4885KDM4E 1816/4885HSD17B10 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.